Ipca Laboratories has achieved satisfactory financial performance during the year ended March 2011 and its consolidated net profit increased by 28 per cent to Rs.262.82 crore from Rs.205.36 crore in the previous year, Its consolidated net sales also improved by 20.7 per cent to Rs.1,883 crore from Rs.1,560 crore. The earnings per share went up to Rs.20.96 from Rs.16.44.
The Board has recommended a final dividend of Rs.1.20 per share of Rs.2 each and it worked out to 60 per cent for the year 2010-11. Earlier, the company paid interim dividend of Rs.2 per share (100 per cent). Thus the total dividend worked out to 160 per cent.
Ipca's EBDITA increased by 13.2 per cent to Rs.384.44 crore from Rs.339.66 crore. Its other operating income increased to Rs.16.32 crore from Rs.7.21 crore. Employees cost increased to Rs.266.28 crore from Rs.220.70 crore, a growth of 20.7 per cent.
The company's reserves and surplus increased by 22.2 per cent to Rs.1,026 crore from Rs.840 crore and its fixed assets moved up by 20.2 per cent to Rs.812 crore from Rs.676 crore.